New research about the harms of long-acting opioids may underestimate risks, members of two FDA advisory committees said Monday. Data did not represent large segments of the U.S. population and relied ...
Opioid abuse during pregnancy is on the rise, new research suggests—and that’s likely to endanger both expectant mothers and their children. Researchers at Oregon Health & Science University (OHSU) ...
The US Food and Drug Administration (FDA) has approved a 10-mg dose of Roxybond (Protega Pharmaceuticals), an opioid analgesic indicated for the management of severe pain in cases where other ...
Could sex hormones explain the difference in opioid use and misuse between genders? Since 1999, the American opioid epidemic has killed more than half a million people, and according to the National ...
A novel opioid developed by National Institutes of Health researchers has shown early potential to deliver powerful pain ...
Troxyca extended-release tablets are intended to treat patients that require daily, long-term opioid treatment to manage severe pain. The tablets contain pellets of oxycodone hydrochloride, an opioid ...
The FDA has approved the first abuse-deterrent, immediate-release, 10 mg opioid tablet for pain management, signing off on another dosage of Protega Pharmaceuticals’ Roxybond. The nod covers those ...
National Institutes of Health researchers have identified a compound called N-desethyl-fluornitrazene, or DFNZ, that delivered strong pain relief in rodents while sharply reducing the respiratory ...
He argued the settlements were made due to the thousands of people who have died by opioid overdoses and those families need ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results